(Q39097489)

9 September 2017

title

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis (English)

1 reference

9 September 2017

0 references

Julia Wilkerson

1

0 references

Susan E Bates

15

object named as

Susan E Bates

1 reference

9 September 2017

16

Tito Fojo

1 reference

9 September 2017

11

Howard I Scher

1 reference

9 September 2017

Kald Abdallah

2

1 reference

9 September 2017

Charles Hugh-Jones

3

1 reference

9 September 2017

Greg Curt

4

1 reference

9 September 2017

Mace Rothenberg

5

1 reference

9 September 2017

Ronit Simantov

6

1 reference

9 September 2017

Martin Murphy

7

1 reference

9 September 2017

Joseph Morrell

8

1 reference

9 September 2017

Joel Beetsch

9

1 reference

9 September 2017

Daniel J Sargent

10

1 reference

9 September 2017

Peter Lebowitz

12

1 reference

9 September 2017

Richard Simon

13

1 reference

9 September 2017

Wilfred D Stein

14

1 reference

9 September 2017

publication date

12 December 2016

1 reference

Lancet Oncology Commission

9 September 2017

published in

1 reference

9 September 2017

volume

18

1 reference

9 September 2017

issue

1

1 reference

9 September 2017

page(s)

143-154

1 reference

Why do phase III clinical trials in oncology fail so often?

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Abiraterone in metastatic prostate cancer without previous chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Time course of imaging changes of GBM during extended bevacizumab treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Update on second primary malignancies in multiple myeloma: a focused review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930633-7

7 January 2021

10.1016/S1470-2045(16)30633-7

Identifiers

DOI

1 reference

9 September 2017

1 reference